



## OPEN ACCESS

## EDITED BY

Alberto Albanese,  
Catholic University of the Sacred Heart, Italy

## REVIEWED BY

Jacky Ganguly,  
Institute of Neurosciences, Kolkata (I-NK), India  
Cecile Gallea,  
INSERM U1127 Institut du Cerveau et de la  
Moelle épinière (ICM), France

## \*CORRESPONDENCE

Alexander Calvano

✉ alexander.calvano@staff.uni-marburg.de

RECEIVED 12 June 2023

ACCEPTED 06 September 2023

PUBLISHED 26 September 2023

## CITATION

Calvano A, Beccaria L, Timmermann L,  
Bopp MHA, Gjorgjevski M, Nimsky C and  
Pedrosa DJ (2023) Case report: Unilateral  
GPi DBS in secondary myoclonus-dystonia  
syndrome after acute disseminated  
encephalomyelitis.

*Front. Neurol.* 14:1238743.

doi: 10.3389/fneur.2023.1238743

## COPYRIGHT

© 2023 Calvano, Beccaria, Timmermann,  
Bopp, Gjorgjevski, Nimsky and Pedrosa. This is  
an open-access article distributed under the  
terms of the [Creative Commons Attribution  
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or  
reproduction in other forums is permitted,  
provided the original author(s) and the  
copyright owner(s) are credited and that the  
original publication in this journal is cited, in  
accordance with accepted academic practice.  
No use, distribution or reproduction is  
permitted which does not comply with these  
terms.

# Case report: Unilateral GPi DBS in secondary myoclonus-dystonia syndrome after acute disseminated encephalomyelitis

Alexander Calvano<sup>1\*</sup>, Laura Beccaria<sup>1</sup>, Lars Timmermann<sup>1,2</sup>,  
Miriam H. A. Bopp<sup>2,3</sup>, Marko Gjorgjevski<sup>3</sup>, Christopher Nimsky<sup>2,3</sup>  
and David J. Pedrosa<sup>1,2</sup>

<sup>1</sup>Department of Neurology, Philipps-University Marburg, Marburg, Germany, <sup>2</sup>Center for Mind, Brain and Behaviour (CMBB), Marburg, Germany, <sup>3</sup>Department of Neurosurgery, Philipps-University Marburg, Marburg, Germany

**Introduction:** Deep brain stimulation (DBS) is an established and effective therapy for movement disorders. Here, we present a case of secondary myoclonus-dystonia syndrome following acute disseminated encephalomyelitis (ADEM) in childhood, which was alleviated by DBS. Using a patient-specific connectome analysis, we sought to characterise the fibres and circuits affected by stimulation.

**Case report:** We report a case of a 20-year-old man with progressive dystonia, myoclonic jerks, and impaired concentration following childhood ADEM. Motor assessments utilising the Unified Myoclonus Rating Scale (UMRS) and the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) revealed a greater improvement in dystonia compared to myoclonus following adjustments of DBS parameters. These adjustments were based on visualisation of electrode position and volume of tissue activated (VTA) 3 years after surgery. A patient-specific connectome analysis using the VTA as a region of interest revealed fibre tracts connecting to the cerebello-thalamo-cortical network and the superior frontal gyrus in addition to basal ganglia circuits as particularly effective.

**Conclusion:** Globus pallidus internus (GPi) DBS shows promise as a treatment for secondary myoclonus-dystonia syndromes. Personalised structural considerations, tailored to individual symptoms and clinical characteristics, can provide significant benefits. Patient-specific connectome analysis, specifically, offers insights into the structures involved and may enable a favourable treatment response.

## KEYWORDS

myoclonus-dystonia, acute disseminated encephalomyelitis, deep brain stimulation, neuromodulation, connectome analysis

## 1. Introduction

Acute disseminated encephalomyelitis (ADEM) is a neuroinflammatory disorder characterised by central nervous system demyelination. Whereas the exact pathomechanisms remain elusive, the thalamus and the basal ganglia are commonly affected (1). Involvement of pathways within these motor circuits may result in complex secondary movement disorders (2), which necessitate tailored

treatments according to individual clinical characteristics. Meanwhile deep brain stimulation (DBS) targeting these pathological network dynamics may also provide valuable insights into symptom-specific structural correlates, given its efficacy to a plethora of movement disorders such as dystonia (3) and hereditary myoclonus-dystonia (4). However, due to clinical heterogeneity and limited systematic analyses, accurately predicting outcomes of DBS for secondary dystonia syndromes is challenging. This uncertainty in prediction may lead to the cautious application of DBS beyond routine clinical practise, potentially resulting in the withholding of this effective treatment from certain patients (5). This report presents a case of secondary myoclonus-dystonia syndrome following ADEM in childhood, alleviated by DBS surgery at the internal part of the globus pallidus (GPi). We used a patient-specific connectome analysis to investigate the fibres and circuits modulated by stimulation.

## 2. Case presentation

We evaluated a 20-year-old male patient with a history of progressive dystonia, myoclonic jerks, speech difficulties, and impaired concentration. He was diagnosed with ADEM at the age of 10 in November 2009 and underwent several weeks of intensive medical therapy followed by months of rehabilitation. While initial symptoms (meningismus, encephalopathy, and cranial neuropathy) resolved, dystonic symptoms first appeared in December 2009, manifesting as involuntary movements in his right index finger while writing. Over the course of 3 years, the patient's motor symptoms progressed beyond dystonia to myoclonic gestures.

On initial examination, the patient presented with involuntary movements of the right arm and face, which were characterised by focal dysrhythmic jerks that were exacerbated by certain postures, movements, and stimuli. He also presented with multifocal dystonia of the right arm and foot. Brain MRI revealed lesions in the pons, cerebellum, thalamus, and periventricular white matter around the lateral ventricles (Figure 1).

Despite the often self-limiting nature of ADEM, we hypothesised an association between focal demyelination in the thalamus (6–8) and brainstem (7, 8) and delayed onset of symptoms (Figures 1B,C).

Especially in secondary dystonia, the time between structural lesions and the onset of symptoms can be several months or even years (7). In addition, there was no family history of neurological disorders in the entire family.

The patient was thus diagnosed with a secondary multifocal myoclonus-dystonia syndrome following ADEM. Dystonia and myoclonus had remained refractory to anticonvulsants (Piracetam, Levetiracetam) and anticholinergics (Trihexyphenidyl). Following thorough multidisciplinary evaluation, the patient decided to undergo unilateral lead placement in the left GPi using directional leads (Vercise Cartesia™ 2202-02 leads, Boston Scientific Neuromodulation Corporation, Valencia, United States). DBS programming according to monopolar review revealed the largest therapeutic window when the current was steered in the anterior direction of the distal three-segmented ring contact. Using a top-down approach, we gradually increased the stimulation amplitudes to the maximum tolerated voltage while maintaining a frequency of 130 Hz and a pulse width of 60  $\mu$ s. The patient was allowed to adapt DBS settings according to his preferences and was informed about the known long-term effects in dystonia. He deliberately chose programme 2 [C+ 1–(30%), 2–(35%), 3–(35%), 4 mA, 60  $\mu$ s, 130 Hz] because it provided the most significant relief of motor symptoms (Table 1).

During 3 years of follow-up, the patient reported worsening of dystonia and myoclonic jerks. To address these issues, we introduced four new stimulation programmes. In view of reports indicating efficacy of higher stimulation frequencies and pulse widths in the treatment of dystonia (9), increased pulse width (90  $\mu$ s) was used in programme 6, higher frequency (185 Hz) in programme 7, and a combination of increased pulse width and frequency in programme 8, allowing the patient to adjust the settings prospectively. In addition, we used an imaging-guided optimisation of DBS parameters (programme 5) by directing the volume of tissue activated (VTA) towards proximal contacts moving from [C+, 1–(30%), 2–(35%), 3–(35%)] to [C+, 2–(10%), 4–(10%), 5–(40%), 7–(40%); avoiding contacts 3 and 6, respectively] in order to maximise the intersection between VTA and the ventral parts of the GPi, which are in close anatomical proximity to the pallidothalamic tract (PTT) (10). For dystonia, modulation of the PTT has been




FIGURE 1

MRI scans. (A) Axial FLAIR-weighted MRI scans demonstrate periventricular white matter lesions around the lateral ventricles. (B) Coronal FLAIR-weighted MRI with bithalamic hyperintense lesions. (C) Sagittal FLAIR-weighted MRI reveals a hypointense lesion in the pons.

TABLE 1 DBS programming parameters.

Date	GPi DBS				
	Programme	Active contacts	Left		
Amplitude (mA)			Pulse width ( $\mu$ s)	Frequency (Hz)	
July 2019	1	C+ 1–(33%), 2–(33%), 3–(33%)	0.9	60	130
October 2019	2	C+ 1–(30%), 2–(35%), 3–(35%)	4	60	130
	3	C+ 2–(50%), 3–(50%)	1.8	90	130
	4	C+ 2–(50%), 3–(50%)	2	60	185
February 2023	5	C+ 2–(10%), 4–(10%), 5–(40%), 7–(40%)	2	90	185
	6	C+ 1–(30%), 2–(35%), 3–(35%)	3.5	90	130
	7	C+ 1–(30%), 2–(35%), 3–(35%)	5	60	185
	8	C+ 1–(30%), 2–(35%), 3–(35%)	3	90	185

demonstrated to improve symptoms after pallidal DBS (11), while relief of myoclonus has been reported after contralateral pallidothalamic tractotomy (12). For this programme, we set the pulse width to 90  $\mu$ s and the frequency to 185 Hz. A figure illustrating the changes in active DBS contacts after imaging-guided programming is provided as [Supplementary material](#).

We assessed motor symptoms employing the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) and the Unified Myoclonus Rating Scale (UMRS) with DBS turned off and on. This resulted in predominant improvement in dystonia (OFF: 26, ON: 4) relative to myoclonus (OFF: 85, ON: 60) after imaging-guided adjustments of DBS parameters. See [Figure 2](#) for a timeline of the patient's medical history.

## 2.1. Patient-specific connectome analysis

Magnetic resonance imaging data were acquired 1 day before surgery on a 3 T scanner. The preoperative imaging protocol included b-values of 0 and 1,000 s/mm<sup>2</sup> and 30 independent diffusion gradient directions. The DBS lead and VTA visualisation was carried out using the LEAD-DBS software<sup>1</sup> (13, 14). Specifically, we co-registered preoperative diffusion tensor imaging (DTI) to T1 imaging with SPM12<sup>2</sup> and subsequently used Advanced Normalisation Tools (ANTs) to co-register the results with the postoperative CT scan (15). The Precise and Convenient Electrode Reconstruction for Deep Brain Stimulation (PaCER algorithm) (16) facilitated the electrode detection including its rotation. Structural connectivity was analysed using the Generalised Q-Sampling method implemented in DSI Studio<sup>3</sup> (17). The VTA served as a region of interest (ROI) for identifying connected fibre tracts, with an electric field threshold of 0.2 V/mm applied during estimation (18, 19). Using a finite element model, the stimulation volume was computed by estimating the gradient distribution of the electrical charge in space on a tetrahedral mesh that differentiated four

compartments: grey and white matter, electrode contact, and insulation (20), as implemented in LEAD-DBS.

Utilising the DISTAL Minimal Atlas to define parcellation of grey matter structures (21), the VTA mostly overlapped with the prefrontal and sensorimotor subregions of the GPi ([Supplementary Figure 2](#)). As expected, our findings showed that the fibre tracts associated with the VTA of GPi DBS were connected to basal ganglia circuits and the superior frontal gyrus (SFG), which was characterised by the A6m region of the Brainnetome atlas (22). Furthermore, these fibre tracts were found to overlap with the dentato-rubro-thalamic tract (DRT), potentially indicating a modulation of the cerebello-thalamo-cortical network, as identified by the DBS tractography atlas (23) ([Figure 3](#)).

## 3. Discussion



To the best of our knowledge, this is the first published case of secondary myoclonus-dystonia syndrome after ADEM successfully treated with unilateral GPi DBS. Adjustments of DBS parameters according to connectomic data for a modulation of distributed brain networks (24) has been used to identify stimulation sweet spots in patients suffering from movement disorders such as Parkinson's disease (25, 26) and paediatric dystonia (27). In our patient, predominant improvement of dystonia relative to myoclonus was observed when the VTA was steered to overlap prefrontal and sensorimotor subregions of the GPi. This is consistent with recent findings suggesting that pallidal DBS effectively normalises dystonia-associated sensorimotor and prefrontal hyperactivity, which have been implicated in the pathophysiology of dystonia (28).

For secondary movement disorders, growing evidence highlights a key role of alterations in multiple anatomical pathways (29). For dystonia and myoclonus in particular, desynchronisation of the cortico-basal ganglia-cerebellar network has been put forward as an underlying mechanism (30). Our results indicate an alleviation of both symptoms upon modulation of basal ganglia circuits with fibre tracts intersecting the DRT and projecting to the SFG. The interpretation of a complex multinet model seems to be corroborated by findings indicating a synchronicity of pallidal oscillations and myoclonic jerks (31), whereas secondary myoclonus may also result from lesions in the cerebellum (32).

1 <https://www.lead-dbs.org>

2 <http://www.fil.ion.ucl.ac.uk/spm/software/>

3 <https://dsi-studio.labsolver.org>



While DBS targeting the posterior part of the ventrolateral thalamic nucleus (VLp) can effectively address myoclonus (33, 34), in our patient, right-sided dystonic features were the predominant symptom, causing significant difficulties with activities of daily-living and severely affecting the patient’s quality of life. This led us to choose the left GPi as the most appropriate target for DBS treatment, given its widely demonstrated efficacy for ameliorating dystonia (3). While this case highlights the importance of a thorough clinical assessment as the basis for selecting stimulation targets, future insights from patient-specific connectivity profiles could improve our understanding of the underlying neural dynamics and provide insights into the precise target for DBS leads in rare movement disorders.

### 3.1. Limitations

While this case report demonstrates the long-term effects of pallidal DBS in a secondary myoclonus-dystonia syndrome and thereby highlights the underlying networks, there are some limitations. Although imaging-guided optimisation of DBS parameters was carried out based on the VTA and its adjacent neuroanatomical structures, the stimulation parameters were not refined using the tractography results from the patient-specific connectome analysis. In addition, our preoperative imaging protocol prevented us from testing for abnormal kurtosis measures. Diffusion kurtosis imaging (DKI) has been shown to be more sensitive to microstructural changes in



demyelinating disorders (35) by quantifying the deviation of the water diffusion displacement profile from the Gaussian distribution (36). Another limitation is reflected in the absence of functional data, which may have provided supplementary insights into alterations in neural connectivity. Finally, this report describes a single case and therefore the findings may not be generalisable to a broader population. Despite these limitations, future studies could explore the potential of using patient-specific connectome analyses to fine-tune DBS parameters for movement disorders, tailoring the treatment based on individual symptoms and clinical characteristics.

## Data availability statement

The datasets presented in this article are not readily available because of ethical and privacy restrictions. Requests to access the datasets should be directed to the corresponding author.

## Ethics statement

Ethical review and approval was not required for this case report in accordance with the local legislation and institution requirements. The patient provided written informed consent for the use of anonymized data for research purposes and for publication of any potentially identifiable images or data included in this article.

## Author contributions

AC and LB collected the clinical data and co-wrote the manuscript. AC performed the image analysis. MG, MB, and CN contributed to the data curation. LT and DP confirmed the diagnosis of the case and supervised the study. All authors contributed to the article and approved the submitted version.

## Funding

AC was supported by the travel grant of the Thiemann Foundation. The AC was funded by Marburg University's Open Access Publishing Fund.

## References

- Pohl D, Alper G, Van Haren K, Kornberg AJ, Lucchinetti CF, Tenenbaum S, et al. Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome. *Neurology*. (2016) 87:S38–45. doi: 10.1212/WNL.0000000000002825
- Mehanna R, Jankovic J. Movement disorders in multiple sclerosis and other demyelinating diseases. *J Neurol Sci*. (2013) 15:1–8. doi: 10.1016/j.jns.2013.02.007
- Ostrem JL, Starr PA. Treatment of dystonia with deep brain stimulation. *Neurotherapeutics*. (2008) 5:320–30. doi: 10.1016/j.nurt.2008.01.002
- Wang X, Yu X. Deep brain stimulation for myoclonus dystonia syndrome: a meta-analysis with individual patient data. *Neurosurg Rev*. (2021) 44:451–62. doi: 10.1007/s10143-019-01233-x
- Reese R, Volkmann J. Deep brain stimulation for the Dystonias: evidence, knowledge gaps, and practical considerations. *Mov Disord Clin Pract*. (2017) 4:486–94. doi: 10.1002/mdc3.12519
- Borg M. Symptomatic myoclonus. *Neurophysiol Clin*. (2006) 36:309–18. doi: 10.1016/j.neucli.2006.12.006
- LeDoux MS, Brady KA. Secondary cervical dystonia associated with structural lesions of the central nervous system. *Mov Disord*. (2003) 18:60–9. doi: 10.1002/mds.10301
- Loher TJ, Krauss JK. Dystonia associated with pontomesencephalic lesions. *Mov Disord*. (2009) 24:157–67. doi: 10.1002/mds.22196
- Magown P, Andrade RA, Soroceanu A, Kiss ZH. Deep brain stimulation parameters for dystonia: a systematic review. *Parkinsonism Relat Disord*. (2018) 54:9–16. doi: 10.1016/j.parkreldis.2018.04.017
- Koeglsperger T, Palleis C, Hell F, Mehrkens JH, Bötzel K. Deep brain stimulation programming for movement disorders: current concepts and evidence-based strategies. *Front Neurol*. (2019) 10:410. doi: 10.3389/fneur.2019.00410
- Rozanski VE, da Silva NM, Ahmadi SA, Mehrkens J, da Silva CJ, Houde JC, et al. The role of the pallidothalamic fibre tracts in deep brain stimulation for dystonia: a diffusion MRI tractography study. *Hum Brain Mapp*. (2017) 38:1224–32. doi: 10.1002/hbm.23450
- Horisawa S, Miyao S, Hori T, Kohara K, Kawamata T, Taira T. Comorbid seizure reduction after pallidothalamic tractotomy for movement disorders: revival of Jinnai's Forel-H-tomy. *Epilepsia Open*. (2021) 6:225–9. doi: 10.1002/epi4.12467
- Horn A, Kühn AA. Lead-DBS: a toolbox for deep brain stimulation electrode localizations and visualizations. *NeuroImage*. (2015) 107:127–35. doi: 10.1016/j.neuroimage.2014.12.002

## Conflict of interest

AC has participated in a training course which was industry funded by Stada Arzneimittel AG. LT reports grants, personal fees, and non-financial support from SAPIENS Steering Brain Stimulation, Medtronic, Boston Scientific, and St. Jude Medical, and has received payments from Bayer Healthcare, UCB Schwarz Pharma, and Archimedes Pharma and also honoraria as a speaker on symposia sponsored by Teva Pharma, Lundbeck Pharma, Bracco, Gianni PR, Medas Pharma, UCB Schwarz Pharma, Desitin Pharma, Boehringer Ingelheim, GSK, Eumecom, Orion Pharma, Medtronic, Boston Scientific, Cephalon, Abbott, GE Medical, Archimedes, and Bayer. DP received honoraria as a speaker at symposia sponsored by Boston Scientific Corp, Medtronic, AbbVie Inc., Zambon, and Esteve Pharmaceuticals GmbH. He received payments as a consultant for Boston Scientific Corp and Bayer, and he received a scientific grant from Boston Scientific Corp for a project entitled: 'Sensor-based optimisation of Deep Brain Stimulation settings in Parkinson's disease' (COMPARE-DBS). Finally, DP was reimbursed by Esteve Pharmaceuticals GmbH and Boston Scientific Corp for travel expenses to attend congresses.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fneur.2023.1238743/full#supplementary-material>

14. Horn A, Li N, Dembek TA, Kappel A, Boulay C, Ewert S, et al. Lead-DBS v2: towards a comprehensive pipeline for deep brain stimulation imaging. *NeuroImage*. (2019) 184:293–316. doi: 10.1016/j.neuroimage.2018.08.068
15. Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. *NeuroImage*. (2011) 54:2033–44. doi: 10.1016/j.neuroimage.2010.09.025
16. Husch A, Petersen MV, Gemmar P, Goncalves J, Hertel F. PaCER-A fully automated method for electrode trajectory and contact reconstruction in deep brain stimulation. *Neuroimage Clin*. (2018) 17:80–9. doi: 10.1016/j.nicl.2017.10.004
17. Yeh FC, Wedeen VJ, Tseng WY. Generalized q-sampling imaging. *IEEE Trans Med Imaging*. (2010) 29:1626–35. doi: 10.1109/TMI.2010.2045126
18. Horn A, Neumann WJ, Degen K, Schneider GH, Kühn AA. Toward an electrophysiological “sweet spot” for deep brain stimulation in the subthalamic nucleus. *Hum Brain Mapp*. (2017) 38:3377–90. doi: 10.1002/hbm.23594
19. Åström M, Diczfalusy E, Martens H, Wårdell K. Relationship between neural activation and electric field distribution during deep brain stimulation. *IEEE Trans Biomed Eng*. (2014) 62:664–72. doi: 10.1109/TBME.2014.2363494
20. Horn A, Reich M, Vorwerk J, Li N, Wenzel G, Fang Q, et al. Connectivity predicts deep brain stimulation outcome in Parkinson disease. *Ann Neurol*. (2017) 82:67–78. doi: 10.1002/ana.24974
21. Ewert S, Plettig P, Li N, Chakravarty MM, Collins DL, Herrington TM, et al. Toward defining deep brain stimulation targets in MNI space: a subcortical atlas based on multimodal MRI, histology and structural connectivity. *NeuroImage*. (2018) 170:271–82. doi: 10.1016/j.neuroimage.2017.05.015
22. Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, et al. The human Brainnetome atlas: a new brain atlas based on connective architecture. *Cereb Cortex*. (2016) 26:3508–26. doi: 10.1093/cercor/bhw157
23. Middlebrooks EH, Domingo RA, Vivas-Buitrago T, Okromelidze L, Tsuboi T, Wong JK, et al. Neuroimaging advances in deep brain stimulation: review of indications, anatomy, and brain Connectomics. *AJNR Am J Neuroradiol*. (2020) 41:1558–68. doi: 10.3174/ajnr.A6693
24. Horn A, Wenzel G, Irmen F, Huebl J, Li N, Neumann WJ, et al. Deep brain stimulation induced normalization of the human functional connectome in Parkinson's disease. *Brain*. (2019) 142:3129–43. doi: 10.1093/brain/awz239
25. Sobesky L, Goede L, Odekerken VJJ, Wang Q, Li N, Neudorfer C, et al. Subthalamic and pallidal deep brain stimulation: are we modulating the same network? *Brain*. (2022) 145:251–62. doi: 10.1093/brain/awab258
26. Dembek TA, Roediger J, Horn A, Reker P, Oehrns C, Dafsari HS, et al. Probabilistic sweet spots predict motor outcome for deep brain stimulation in Parkinson disease. *Ann Neurol*. (2019) 86:527–38. doi: 10.1002/ana.25567
27. Al-Fatly B, Giesler SJ, Oxenford S, Li N, Dembek TA, Achztehn J, et al. Neuroimaging-based analysis of DBS outcomes in pediatric dystonia: insights from the GEPESTIM registry. *Neuroimage Clin*. (2023) 39:103449. doi: 10.1016/j.nicl.2023.103449
28. Greuel A, Pauls KAM, Koy A, Südmeyer M, Schnitzler A, Timmermann L, et al. Pallidal deep brain stimulation reduces sensorimotor cortex activation in focal/segmental dystonia. *Mov Disord*. (2020) 35:629–39. doi: 10.1002/mds.27970
29. Ghosh R, Roy D, Dubey S, Das S, Benito-León J. Movement disorders in multiple sclerosis: an update. *Tremor Other Hyperkinet Mov*. (2022) 12:14. doi: 10.5334/tohm.671
30. Milardi D, Quartarone A, Bramanti A, Anastasi G, Bertino S, Basile GA, et al. The Cortico-basal ganglia-cerebellar network: past, present and future perspectives. *Front Syst Neurosci*. (2019) 13:61. doi: 10.3389/fnsys.2019.00061
31. Liu X, Griffin IC, Parkin SG, Miall RC, Rowe JG, Gregory RP, et al. Involvement of the medial pallidum in focal myoclonic dystonia: a clinical and neurophysiological case study. *Mov Disord*. (2002) 17:346–53. doi: 10.1002/mds.10038
32. Shen G, Nan G, Shin CW, Park H, Lee KY, Jeon B. Combined focal myoclonus and dystonia secondary to a cerebellar hemorrhage: a case report. *BMC Neurol*. (2016) 16:228. doi: 10.1186/s12883-016-0745-6
33. Trottenberg T, Meissner W, Kabus C, Arnold G, Funk T, Einhaupl KM, et al. Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. *Mov Disord*. (2001) 16:769–71. doi: 10.1002/mds.1119
34. Kobayashi K, Katayama Y, Otaka T, Obuchi T, Kano T, Nagaoka T, et al. Thalamic deep brain stimulation for the treatment of action myoclonus caused by perinatal anoxia. *Stereotact Funct Neurosurg*. (2010) 88:259–63. doi: 10.1159/000315464
35. Tabesh A, Jensen JH, Ardekani BA, Helpert JA. Estimation of tensors and tensor-derived measures in diffusional kurtosis imaging. *Magn Reson Med*. (2011) 65:823–36. doi: 10.1002/mrm.22655
36. Lazar M, Jensen JH, Xuan L, Helpert JA. Estimation of the orientation distribution function from diffusional kurtosis imaging. *Magn Reson Med*. (2008) 60:774–81. doi: 10.1002/mrm.21725